The Canadian energy companies may be out of favor, but that has not stopped several of them from posting decent operating results. Investors can invest in Canadian companies far more cheaply than Permian operators. Yet, the results in Canada appear every bit as competitive. Obsidian Energy (OBE) just reported about C$.38 per share cash flow. That is very roughly one-fourth of the current selling price. Cash flow increased despite the WCS price weakness and all the headlines about the challenges facing Canadian producers.
Source: Obsidian Energy Fourth Quarter 2018 Earnings Press Release
Top Energy Stocks To Invest In 2019: bluebird bio, Inc.(BLUE)
- [By Rafi Farber]
Heres some perspective. Within the past decade, University of Pennsylvania has allied with Novartis A.G. (NYSE: NVS), Baylor College of Medicine with Bluebird Bio Inc. (NASDAQ: BLUE) and Celgene Corp. (NASDAQ:CELG), Memorial Sloan Kettering Cancer Center and the Fred Hutchinson Cancer Research Center with Juno Therapeutics Inc. (NASDAQ: JUNO) (which Celgene just got clearance to acquire), and the National Cancer Institute with Kite Pharma, which was acquired last year byGilead Sciences Inc. (NASDAQ: GILD).
- [By Ethan Ryder]
Blue Protocol (CURRENCY:BLUE) traded down 9.1% against the U.S. dollar during the 24-hour period ending at 11:00 AM Eastern on May 12th. One Blue Protocol token can now be purchased for about $0.18 or 0.00002166 BTC on cryptocurrency exchanges including CoinExchange, EtherDelta (ForkDelta), IDEX and YoBit. In the last seven days, Blue Protocol has traded down 16.3% against the U.S. dollar. Blue Protocol has a market capitalization of $6.65 million and $31,443.00 worth of Blue Protocol was traded on exchanges in the last 24 hours.
- [By Chris Lange]
Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.
- [By Todd Campbell, Leo Sun, and Daniel Miller]
For instance, the company recently acquired Juno Therapeutics to get its hands on a pipeline of chimeric antigen receptor T-cell gene therapies (CAR-Ts). CAR-Ts represent one of the biggest recent advances in treating blood cancer, and depending on trial results, the first CAR-T from this collaboration could be filed for approval next year. Similarly, Celgene is partnering with bluebird bio (NASDAQ:BLUE) on bb2121, a CAR-T for multiple myeloma. So far, bb2121 is delivering 90%-plus response rates in heavily pre-treated patients, and if that success continues, it could end up on regulators’ desk for approval next year, too.
- [By Keith Speights]
Over the last 12 months, bluebird bio (NASDAQ:BLUE) stock has more than doubled. During the same period, Ziopharm Oncology’s (NASDAQ:ZIOP) share price has tumbled over 30%. That’s the past, though. Which of these two clinical-stage biotech stocks is the better pick for investors now?
- [By Brian Orelli]
bluebird bio (NASDAQ:BLUE) reportedfirst-quarter earnings last week, but like the biotech typically does, management didn’t hold a conference call, which makes the earnings release more of a rehash of the quarter than an actual update.
Top Energy Stocks To Invest In 2019: Wabash National Corporation(WNC)
- [By Tyler Crowe]
It wasn’t that long ago that concerns about a downturn in the truck trailer business had investors concerned that Wabash National’s (NYSE:WNC) best days were behind it. Those concerns seem to have been overblown, though, as demand for Wabash’s products were high enough for management to raise its sales guidance for the year.
Top Energy Stocks To Invest In 2019: Littelfuse Inc.(LFUS)
- [By Joseph Griffin]
Littelfuse (NASDAQ:LFUS) Director John E. Major sold 1,648 shares of the company’s stock in a transaction that occurred on Friday, May 11th. The shares were sold at an average price of $215.86, for a total value of $355,737.28. Following the completion of the transaction, the director now directly owns 26,254 shares in the company, valued at approximately $5,667,188.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
- [By Ethan Ryder]
Littelfuse (NASDAQ:LFUS) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday.
- [By Stephan Byrd]
Littelfuse (NASDAQ: LFUS) and ABB Group (NYSE:ABB) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.